EGFR and neoplasm: In esophageal squamous cell carcinoma (ESCC), 64Cu-cetuximab was shown to be useful in detecting EGFR-expressing tumors using PET imaging; however, 64Cu-cetuximab tumor accumulation only peaked at 48 hours (h), indicating that a desired image was produced 2 days later [24].